Overview
- Editors:
-
-
Pablo Avanzas
-
Department of Cardiology, Hospital Universitario Central de Asturias, Oviedo, Spain
-
Juan Carlos Kaski
-
Cardiovascular and Cell Sciences Research Institute, St George's University of London, London, United Kingdom
- Provides a concise overview of chronic stable angina (CSA)
- Reviews potential treatment strategies for CSA
- Written by an international authorship of experts in the area
Access this book
Other ways to access
Table of contents (12 chapters)
-
-
-
- Jason M. Tarkin, Juan Carlos Kaski
Pages 33-56
-
- Esteban López-de-Sá, José López-Sendón
Pages 57-77
-
-
- Amelia Carro, Pablo Avanzas
Pages 87-114
-
- Jason M. Tarkin, Juan Carlos Kaski
Pages 115-134
-
- Alberto Dominguez-Rodriguez
Pages 135-152
-
- Alda Huqi, Giacinta Guarini, Doralisa Morrone, Mario Marzilli
Pages 153-172
-
- Giuseppe M. C. Rosano, Cristiana Vitale, Maurizio Volterrani
Pages 173-188
-
-
- Isaac Pascual, Pablo Avanzas, Raquel del Valle, César Morís
Pages 235-264
-
- Mariagrazia Stracquadanio, Lilliana Ciotta
Pages E1-E1
-
Back Matter
Pages 265-278
About this book
This book is intended for general cardiologists and other physicians involved in the care of patients with chronic stable angina (CSA). The goal of this book is to update clinicians on recent data on the medical management of patients with CSA. Ischemic heart disease remains a major public health problem. Chronic stable angina is the initial manifestation of ischemic heart disease in approximately one half of patients. Stable coronary artery disease is generally characterized by episodes of reversible myocardial demand/supply mismatch, related to ischaemia or hypoxia, which are usually inducible by exercise, emotion or other stress and reproducible—but, which may also be occurring spontaneously. Such episodes of ischaemia/hypoxia are commonly associated with transient chest discomfort (angina pectoris). The aim of the management of CSA is to reduce symptoms and improve prognosis. The management of these patients encompasses lifestyle modification, control of coronary artery disease risk factors, evidence-based pharmacological therapy and patient education. All patients with stable angina should be offered optimal medical treatment, defined as one or two anti-anginal drugs as necessary, plus drugs for secondary prevention of cardiovascular disease. Regarding the role of revascularization, randomised trials provide compelling evidence that myocardial revascularisation by coronary artery bypass grafting or by percutaneous coronary intervention improves symptoms of angina relative to continued medical treatment.
Reviews
“This comprehensive book discusses the various medical therapies available to manage angina pectoris. … The book is aimed at a wide range of clinicians including medical students, interns, residents, general cardiologists, and interventional cardiologists. … This book would be a valuable addition to the library of any cardiologist or aspiring cardiologist interested in the medical management of angina.” (Arthur Menezes, Doody's Book Reviews, August, 2015)
Editors and Affiliations
-
Department of Cardiology, Hospital Universitario Central de Asturias, Oviedo, Spain
Pablo Avanzas
-
Cardiovascular and Cell Sciences Research Institute, St George's University of London, London, United Kingdom
Juan Carlos Kaski
About the editors
Dr Pablo Avanzas is a Consultant in Interventional Cardiology at Hospital Universitario Central de Asturias in Oviedo, Spain. Dr Juan Carlos Kaski is Head of the Cardiovascular Sciences Research Centre at St George's University of London (UK) and President of the International Society of Cardiovascular Pharmacotherapy.
